Effect of Repeated Administration of KT3-671, a Nonpeptide AT1 Receptor Antagonist, on Diurnal Variation in Blood Pressure, Heart Rate, and Locomotor Activity in Stroke-Prone Spontaneously Hypertensive Rats as Determined by Radiotelemetry

Koichiro Kawashima, Hideto Amano, Kazuko Fujimoto, Takeshi Suzuki, Takeshi Fujii, Seiichiro Mochizuki, Akira Tomiyama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalJournal of Cardiovascular Pharmacology
Volume27
Issue number3
Publication statusPublished - 1996

Fingerprint

Inbred SHR Rats
Locomotion
Heart Rate
Stroke
Blood Pressure
Hypertension
Photoperiod
Therapeutics
Circadian Rhythm
KT3 671
Cardiac Output
Antihypertensive Agents
Blood Vessels
Arterial Pressure
Motor Activity

Keywords

  • At, receptor antagonist
  • Diurnal blood pressure rhythm
  • Heart rate
  • KT3-671
  • Radiotelemetry
  • Stroke-prone spontaneously hypertensive rats

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

@article{f883b30ad467464bb884e15cd77def2e,
title = "Effect of Repeated Administration of KT3-671, a Nonpeptide AT1 Receptor Antagonist, on Diurnal Variation in Blood Pressure, Heart Rate, and Locomotor Activity in Stroke-Prone Spontaneously Hypertensive Rats as Determined by Radiotelemetry",
abstract = "KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.",
keywords = "At, receptor antagonist, Diurnal blood pressure rhythm, Heart rate, KT3-671, Radiotelemetry, Stroke-prone spontaneously hypertensive rats",
author = "Koichiro Kawashima and Hideto Amano and Kazuko Fujimoto and Takeshi Suzuki and Takeshi Fujii and Seiichiro Mochizuki and Akira Tomiyama",
year = "1996",
language = "English",
volume = "27",
pages = "411--416",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of Repeated Administration of KT3-671, a Nonpeptide AT1 Receptor Antagonist, on Diurnal Variation in Blood Pressure, Heart Rate, and Locomotor Activity in Stroke-Prone Spontaneously Hypertensive Rats as Determined by Radiotelemetry

AU - Kawashima, Koichiro

AU - Amano, Hideto

AU - Fujimoto, Kazuko

AU - Suzuki, Takeshi

AU - Fujii, Takeshi

AU - Mochizuki, Seiichiro

AU - Tomiyama, Akira

PY - 1996

Y1 - 1996

N2 - KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.

AB - KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and loco-motor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Al-though KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hypertension.

KW - At, receptor antagonist

KW - Diurnal blood pressure rhythm

KW - Heart rate

KW - KT3-671

KW - Radiotelemetry

KW - Stroke-prone spontaneously hypertensive rats

UR - http://www.scopus.com/inward/record.url?scp=0029918615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029918615&partnerID=8YFLogxK

M3 - Article

C2 - 8907803

AN - SCOPUS:0029918615

VL - 27

SP - 411

EP - 416

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -